JP4831540B2 - 経口催眠剤及び催眠性飲食物 - Google Patents
経口催眠剤及び催眠性飲食物 Download PDFInfo
- Publication number
- JP4831540B2 JP4831540B2 JP2005245420A JP2005245420A JP4831540B2 JP 4831540 B2 JP4831540 B2 JP 4831540B2 JP 2005245420 A JP2005245420 A JP 2005245420A JP 2005245420 A JP2005245420 A JP 2005245420A JP 4831540 B2 JP4831540 B2 JP 4831540B2
- Authority
- JP
- Japan
- Prior art keywords
- sleep
- hypnotic
- oral
- glutathione
- gsh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000147 hypnotic effect Effects 0.000 title claims description 20
- 235000013305 food Nutrition 0.000 title description 15
- 239000003326 hypnotic agent Substances 0.000 title description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 70
- 229960003180 glutathione Drugs 0.000 claims description 34
- 108010024636 Glutathione Proteins 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000007958 sleep Effects 0.000 description 31
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 17
- 108010053070 Glutathione Disulfide Proteins 0.000 description 16
- 230000008452 non REM sleep Effects 0.000 description 13
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 12
- 229940041514 candida albicans extract Drugs 0.000 description 9
- 239000012138 yeast extract Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salts Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001362 glutamatergic neuron Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- FYYHWMGAXLPEAU-OUBTZVSYSA-N magnesium-25 atom Chemical group [25Mg] FYYHWMGAXLPEAU-OUBTZVSYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000003814 preoptic area Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
すなわち本発明は、
(1)グルタチオン又はその塩を有効成分として含有した経口催眠剤、
(2)グルタチオン又はその塩を有効成分として含有した催眠性飲食物、
を提供するものである。
本発明の有効成分であるグルタチオンは、還元型のGSH、酸化型のGSSG、あるいはこれらの混合物であり、その由来は特に制限はないが、精製GSH、精製GSSG、GSHあるいはGSSGを含有した酵母エキスが好ましく、GSSGを含有した酵母エキスは、例えば、特開2004−283125号公報に記載の方法により容易に製造することができる。
また、グルタチオンは、医薬的に許容される塩としても使用することができる。これら塩の種類は特に制限されないが、例えば、塩酸塩、硫酸塩、燐酸塩等の無機塩や、酢酸塩、酒石酸塩、クエン酸塩、トルエンスルホン酸塩等の有機塩、あるいはアルカリ金属塩(例えばナトリウム、カリウム等)等を例示することができる。
例えば、固体剤形としては、錠剤、顆粒剤、細粒剤、散剤、カプセル剤等が挙げられ、有効成分は、医薬上許容し得る不活性担体、例えばラクトース、スターチ等と混合される。さらに、通常に使用される他の物質、例えば潤滑剤、結合剤、賦形剤、崩壊剤等を添加することもできる。
また、液体剤形としては、医薬上許容し得る不活性希釈剤を含み、潤滑剤、保存剤等を添加することもできる。
飲食物の種類としては、パン類、クッキー、ゼリー等の菓子類、ヨーグルト等の食品、飲料水、牛乳などの飲料を例示することができる。
調製方法も任意であり、例えば、食品・飲料組成物中に有効成分を配合してパン類、菓子類、飲料水等の飲食物を調製したり、ヨーグルト、飲料水、牛乳等の飲食物に添加剤として有効成分を添加・配合して調製することもできるが、グルタチオンの融点以上の温度で処理することは好ましくない。
また、栄養補助食品としてもよく、有効成分の他、ビタミン類、ミネラル、酸化防止剤、フレーバー、生理学的に許容し得る担体、あるいは他の栄養補助食品等を添加することができる。
実施例1
脳波及び筋電図用電極を装着したSprague−Dawley系雄ラット(体重300g、60−70日令)5匹を用い、睡眠データ記録用飼育ゲージ(幅25cm、高さ36cm、奥行き35cm)に移し6日間飼育環境に馴らした後、GSHあるいは対照としてVehicle(蒸留水)を経口投与した。飼育環境は、明期を06:00−18:00、暗期を18:00−06:00、室温を25±1℃、湿度を60±6%とした。
GSH(50mg/ml/rat)あるいはVehicle(1ml)は、暗期の始まる20分前に経口投与し、暗期の始まる18:00から暗期の終わる06:00まで12時間にわたり脳波、筋電図、行動量を連続記録した。
睡眠状態の判定は、覚醒(W)、ノンレム睡眠(NREM)及びレム睡眠(REM)の3状態を脳波、筋電図の連続記録から自動判定した後、さらに視察判定した。
その結果、GSH投与群ではVehicleに比べて統計的有意(P<0.05)な全睡眠量(NREM+REM)及びノンレム睡眠量の増加を示した。
図1に、暗期12時間の全睡眠量(a)、ノンレム睡眠量(b)、レム睡眠量(c)を示す。
実施例1において、GSHにかえて、GSSG、GSH含有酵母エキス(興人製、ハイチオンエキスYH−15、GSH含有量15%、GSSG含有量1%)、GSSG含有酵母エキス(特開2004−283125号公報実施例2に準じて製造したもの、GSSG含有量15%、GSH含有量10%)を用いた以外、実施例1と同様に実施した(投与量、いずれも50mg/ml/rat)。なお、対照となるVehicleは、全実験工程の最初(Vehicle1)、中間(Vehicle2)及び全ての試料投与を終えた後(Vehicle3)の3回投与した。
図2に、暗期12時間の全睡眠量(a)、ノンレム睡眠量(b)、レム睡眠量(c)を示す。
澱粉25重量部、粉糖10重量部、ステアリン酸マグネシウム4重量部及びGSH50重量部を均一に混合し、次いで澱粉シロップ(17%)を適量添加し、顆粒化、乾燥して、本発明の経口催眠剤(顆粒剤)(活性成分:GSH)を得た。
微結晶性セルロース69.5重量部、ステアリン酸マグネシウム0.4重量部及びGSSG25重量部を均一に混合し、圧縮成型した後、粉砕し、これにカルボキシメチルセルロースカルシウム5重量部及びステアリン酸マグネシウム0.1重量部を加えて混合し、打錠機にて圧縮成型して一錠200mgの本発明の経口催眠剤(錠剤)(活性成分:GSSG)を得た。
果糖ブドウ糖液糖5.0重量部、クエン酸ナトリウム0.6重量部、L−アスコルビン酸3.0重量部、GSSG含有酵母エキス5重量部を水86.4重量部に溶解し、本発明の清涼飲料水を得た。
Claims (1)
- グルタチオン又はその塩を有効成分として含有した経口催眠剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005245420A JP4831540B2 (ja) | 2005-08-26 | 2005-08-26 | 経口催眠剤及び催眠性飲食物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005245420A JP4831540B2 (ja) | 2005-08-26 | 2005-08-26 | 経口催眠剤及び催眠性飲食物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007055962A JP2007055962A (ja) | 2007-03-08 |
JP4831540B2 true JP4831540B2 (ja) | 2011-12-07 |
Family
ID=37919745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005245420A Active JP4831540B2 (ja) | 2005-08-26 | 2005-08-26 | 経口催眠剤及び催眠性飲食物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4831540B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008056628A (ja) * | 2006-09-01 | 2008-03-13 | Fancl Corp | 睡眠誘導剤、ストレス性不眠症改善剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH049336A (ja) * | 1990-04-26 | 1992-01-14 | Yasuo Komoda | 催眠剤 |
JPH0474135A (ja) * | 1990-07-13 | 1992-03-09 | Kanegafuchi Chem Ind Co Ltd | 点眼組成物 |
JPH10265402A (ja) * | 1997-03-21 | 1998-10-06 | Kohjin Co Ltd | 魚類のストレス緩和・改善剤およびその方法 |
IT1306130B1 (it) * | 1999-04-16 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti. |
-
2005
- 2005-08-26 JP JP2005245420A patent/JP4831540B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2007055962A (ja) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4203120B2 (ja) | 口腔内用殺菌剤、及び該殺菌剤を含有する食品添加剤 | |
JPWO2018052020A1 (ja) | 睡眠障害改善剤及び睡眠障害の改善方法 | |
WO2013051728A1 (ja) | 睡眠の質改善剤 | |
TW200913988A (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
EP3115047B1 (en) | Debility preventative | |
EP3389385A1 (en) | Method and composition for increasing muscle protein synthesis and/or functional strength in mammals as well as method of producing a composition | |
JPH01294631A (ja) | 糖尿性疾患治療予防剤及び飲食、し好物 | |
JP2008247748A (ja) | 透析患者用栄養組成物 | |
JP2005097161A (ja) | 抗疲労用組成物およびこれを含有する食品 | |
WO2006067925A1 (ja) | 肝機能改善剤 | |
JP2008120754A (ja) | 抗疲労剤 | |
JP2008143811A (ja) | 脂質代謝促進組成物 | |
CN107624068B (zh) | 包含肉桂醛和锌的组合物及此类组合物的使用方法 | |
JP4831540B2 (ja) | 経口催眠剤及び催眠性飲食物 | |
JP2005213185A (ja) | エネルギー補給および抗疲労飲食品 | |
JP5917078B2 (ja) | 固形状組成物 | |
JP2007330191A (ja) | メイラード反応を抑制する食品 | |
JP2023154540A (ja) | 加齢性難聴の予防又は改善のための組成物 | |
JP2009013143A (ja) | 睡眠改善用組成物 | |
JP7162917B2 (ja) | 心拍数低下剤 | |
JP5394644B2 (ja) | アスペルロシドまたはその類縁体を含む筋肉増強剤 | |
JP6025538B2 (ja) | 分岐鎖アミノ酸の劣化臭抑制剤及び劣化臭抑制方法 | |
JPH0995448A (ja) | 血中ビオチン濃度の増加方法およびビオチン含有飲食品 | |
US20180280483A1 (en) | Agent for protecting upper respiratory tract and food or drink composition for protecting upper respiratory tract | |
JPWO2008136173A1 (ja) | スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110418 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110908 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110912 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4831540 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140930 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140930 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140930 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |